2076975 2077203
최종편집 2024-04-20 06:03 (토)
MFDS approves Janssen’s urothelial cancer treatment Balversa
상태바
MFDS approves Janssen’s urothelial cancer treatment Balversa
  • Hyeokgi Lee, Newsmp
  • 승인 2022.12.02 01:03
  • 댓글 0
이 기사를 공유합니다

[Newsmp] The Ministry of Food and Drug Safety of South Korea (MFDS, Minister Oh Yoo-kyung) granted Janssen Korea’s orphan drug Balversa to treat urothelial cancer on Nov. 24.

Balversa (Erdafitinib) is a drug that inhibits the proliferation of cancer cells overexpressed due to fibroblast growth factor receptor (FGFR) mutations involved in cell growth and differentiation.

It is expected to provide a new treatment option for patients whose diseases have progressed after receiving existing chemotherapies.

The approved indication for Balversa is adult patients with locally advanced or metastatic urothelial cancer with FGFR2 or FGFR3 genetic alternations that have progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.